Monday December 17, 2018
Home India Punarjeevan a...

Punarjeevan and Pink Chain take up arms against the deadliest disease, Cancer

0
//
Republish
Reprint

IMG_0034

By Ishan Kukreti

In a major endeavor to create awareness about cancer and initiate a constructive dialogue within the society about the same, ‘Pink Chain Cancer Conclave’ was held at the Constitution Club of India on 25th June.

The conclave, which was an initiative by the NGO Punarjeevan, saw discussions on topics relevant to present day ground realities related to the disease and ways to deal with them.

Talking about the causes of cancer, Dr. G.K. Rath, chief of IRCH informed the gathering that while tobacco accounted for 40% of all cancer cases, it is preventable too. If one avoids tobacco in any form, chances of developing cancer drops by 40%.

IMG_0025
                                        Dr. G.K. Rath

 

Throwing light on the issue of tobacco addiction among young adults, Dr. Harit Chaturvedi, Chairman Max Oncology, said that people who start smoking at a young age are at a higher risk of getting addicted. One of the discussions focused on the inclusion of chapters on smoking and its relation to cancer in school books, to sensitize young adults about the ill effects of tobacco.

IMG_0036
Dr. Harit Chaturvedi

 

“The present budget allocations to the healthcare sector in India are abysmally low. Plus, a major chunk of the work in India is toeing the line of western concerns. For example, most of the efforts in cancer healthcare for women is directed towards Breast cancer, because it is a global phenomenon. However, Cervical cancer which to this day claims the highest number female lives remains largely overlooked,” a highly dedicated and equally concerned President of Punarjeevan, Dr. Abhishek Shankar told NewsGram.

Dr. Abhishek Shankar
Dr. Abhishek Shankar
Click here for reuse options!
Copyright 2015 NewsGram

Next Story

New Drug to Give Hopes to Bone Marrow Cancer Patients

It reduced the risk of progression or death by more than 50 per cent in both groups

0
Cancer
Cancer Ribbon. Pixabay

A therapeutic drug has been found to improve outcomes and survival rates for patients with a serious type of bone marrow cancer.

In a clinical trial by researchers at Newcastle University in Britain, patients with newly diagnosed myeloma were treated with a drug called lenalidomide.

The results, published in the journal The Lancet Oncology, showed an improvement for those who received lenalidomide drug, compared to those not receiving it.

“This is a major breakthrough as it shows that the long-term use of lenalidomide significantly improves the time myeloma patients stay in remission after initial therapy,” said Professor Graham Jackson from the Northern Institute for Cancer Research at Newcastle.

Myeloma is a cancer of the plasma cells and it can affect several areas of the body, such as the spine, skull, pelvis and ribs. Current treatment usually involves chemotherapy and a stem-cell transplant.

cancer
New drug offers hope for bone marrow cancer patients. Pixabay

“It is a huge step and, importantly, identifies that for younger patients lenalidomide improves their overall survival for this difficult-to-treat bone marrow cancer,” Jackson said.

“Our research highlights that lenalidomide should be considered for newly diagnosed patients following stem-cell transplantation,” he added.

As part of the study, a total of 1,137 newly diagnosed patients were randomly assigned to lenalidomide maintenance therapy and 834 patients to observation – this was after they completed their initial treatment.

Also Read- Narendra Modi Accuses Congress of Aiding Those Who Want to Weaken Army

The results show that lenalidomide can prolong the average remission time by more than two years in younger patients and by well over a year in older, less fit patients.

It reduced the risk of progression or death by more than 50 per cent in both groups. (IANS)